Skip to content
DataLookout
Menu

STEPSNCT07208097

Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 4 more changesShow less
    • Eligibility criteria expanded, about 27 words
    • Trial sites expanded: 2 → 51 locations
    • Secondary endpoints: 11 to 10
    • Study description expanded, about 2 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Oct 15, 2025 to Oct 25, 2025
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Functional Outcomes Measured Via Modified Rankin Score (mRS) of ≤ 3
Timeframe: 180 days post-randomization

Secondary (10)

Functional Outcomes Measured Via Modified Ordinal Rankin Score (mRS)
Functional Outcomes Measured Via Utility Weighted Modified Rankin Score (mRS)
Functional Outcomes Measured Via Modified Rankin Score (mRS) of ≤ 2
Functional Outcomes Measured Via Modified Rankin Score (mRS) of ≤ 1
Functional Outcomes Measured Via eGOS of 4-8
Show 5 moreShow less
Mortality
Health-related quality of daily life
Early neurological improvement
Residual hematoma volume
Clot removal rate

Arms and interventions

MIS+TNKExperimental

In this group, patients receive standard medical treatment plus mininally invasive stereotactic catheter placement followed by hematoma liquefaction and drainage using tenecteplase (TNK). The single dose of tenecteplase is 0.5mg.

Standard medical treatmentNo intervention

Patients randomized to the control group will receive standard medical management according to the 2022 AHA/ASA Guideline for the Management of Spontaneous Intracerebral Hemorrhage.

Procedures: Stereotactic thrombolysis with Tenecteplase

Sites

51 sites in 1 country